NST0023

NST0023 is a potent and selective small-molecule allosteric inhibitor of Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). MALT1 is a paracaspase that plays a critical role in the CBM (CARMA1-BCL10-MALT1) complex, which is essential for NF-κB signaling downstream of the B-cell receptor. Dysregulated MALT1 activity is a hallmark of several B-cell malignancies, including activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) and mantle cell lymphoma (MCL). By inhibiting MALT1's proteolytic and scaffolding functions, NST0023 suppresses the constitutive NF-κB activation that drives tumor cell survival and proliferation. Originally developed by Nesta Therapeutics, the program was acquired by Janssen (Johnson & Johnson) in 2022 to expand its oncology pipeline in hematologic malignancies.

Other names

NST0023NST-0023NST 0023